Tags : Ventana PD-L1 SP142

MedTech Pharma

Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative

Shots: The approval is based on IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with advanced or mTNBC with no prior therapy The Ventana PD-L1 (SP142) assay was used in Roche’s Tecentriq clinical trials to stratify patients and enhances the visual contrast of tumor-infiltrating immune cell staining The Ventana PD-L1 (SP142) […]Read More